[1] JIAN X, YANG D, WANG L, et al. Downregulation of microRNA-200c-3p alleviates the aggravation of venous thromboembolism by targeting serpin family C member 1. Bioengineered. 2021; 12(2):11156-11168.
[2] LEE WS, KIM KI, LEE HJ, et al. The incidence of pulmonary embolism and deep vein thrombosis after knee arthroplasty in Asians remains low: a meta-analysis. Clin Orthop Relat Res. 2013;471(5):1523-1532.
[3] SØGAARD KK, SCHMIDT M, PEDERSEN L, et al. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 2014;130(10): 829-836.
[4] RABINOVICH A, KAHN SR. The postthrombotic syndrome: current evidence and future challenges. J Thromb Haemost. 2017;15(2):230-241.
[5] DE MAESENEER MG, KAKKOS SK, AHERNE T, et al. Editor’s Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2): 184-267.
[6] ZHANG S, ZHAI Z, YANG Y, et al. Pulmonary embolism risk stratification by European Society of Cardiology is associated with recurrent venous thromboembolism: Findings from a long-term follow-up study. Int J Cardiol. 2016;202:275-281.
[7] JONAS JB. Global prevalence of age-related macular degeneration. Lancet Glob Health. 2014;2(2):e65-66.
[8] SCHULTZ NM, BHARDWAJ S, BARCLAY C, et al. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther. 2021;43(10):1792-1818.
[9] WONG WL, SU X, LI X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116.
[10] LAUDE A, CACKETT PD, VITHANA EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1):19-29.
[11] PENNINGTON KL, DEANGELIS MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3:34.
[12] RUDNICKA AR, MACCALLUM PK, WHITELOCKE R, et al. Circulating markers of arterial thrombosis and late-stage age-related macular degeneration: a case-control study. Eye (Lond). 2010;24(7):1199-1206.
[13] THOMAS CJ, MIRZA RG, GILL MK. Age-Related Macular Degeneration. Med Clin North Am. 2021;105(3):473-491.
[14] 王玉琢,沈洪兵.孟德尔随机化研究应用于因果推断的影响因素及其结果解读面临的挑战[J].中华流行病学杂志, 2020,41(8):1231-1236.
[15] SWANSON SA, TIEMEIER H, IKRAM MA, et al. Nature as a Trialist?: Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials. Epidemiology. 2017;28(5):653-659.
[16] EMDIN CA, KHERA AV, KATHIRESAN S. Mendelian Randomization. JAMA. 2017; 318(19):1925-1926.
[17] BIRNEY E. Mendelian Randomization. Cold Spring Harb Perspect Med. 2022;12(4): a041302.
[18] LAWLOR DA, HARBORD RM, STERNE JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133-1163.
[19] HAYCOCK PC, BURGESS S, WADE KH, et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr. 2016;103(4):965-978.
[20] 张明琛,林安,桑志成,等.特应性疾病与骨关节炎的因果关系:一项孟德尔随机化研究[J].中国骨伤,2024,37(9):904-909.
[21] MUKAMAL KJ, STAMPFER MJ, RIMM EB. Genetic instrumental variable analysis: time to call mendelian randomization what it is. The example of alcohol and cardiovascular disease. Eur J Epidemiol. 2020;35(2):93-97.
[22] PARK JH, WACHOLDER S, GAIL MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570-575.
[23] CARTER AR, SANDERSON E, HAMMERTON G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36(5):465-478.
[24] BURGESS S, THOMPSON SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755-764.
[25] BURGESS S, BOWDEN J, FALL T, et al. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2017;28(1):30-42.
[26] YANG Y, XIAN W, WU D, et al. The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study. Front Endocrinol (Lausanne). 2022; 13:917056.
[27] LIN Z, PAN I, PAN W. A practical problem with Egger regression in Mendelian randomization. PLoS Genet. 2022;18(5): e1010166.
[28] BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525.
[29] XU J, ZHANG S, TIAN Y, et al. Genetic Causal Association between Iron Status and Osteoarthritis: A Two-Sample Mendelian Randomization. Nutrients. 2022; 14(18):3683.
[30] GRECO M FD, MINELLI C, SHEEHAN NA, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015; 34(21):2926-2940.
[31] VERBANCK M, CHEN CY, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-698.
[32] 张鹏,孟永,宋硕,等.干性年龄相关性黄斑变性动物模型研究进展[J].中国药理学与毒理学杂志,2023,37(8):621-630.
[33] 赵晓勇,刘弘扬,任原.基于Caprini血栓风险评分及D-二聚体构建老年髋部骨折术后深静脉血栓形成的风险预测模型[J].安徽医药,2024,28(12):2452-2457+2554.
[34] THOMSON RJ, CHAZARO J, OTERO-MARQUEZ O, et al. Subretinal drusenoid deposits and soft drusen: Are They Markers for Distinct Retinal Diseases? Retina. 2022; 42(7):1311-1318.
[35] 金明,陈有信.中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)[J].中国中西医结合杂志,2021,41(2):151-156.
[36] 成龙,张传伟,薛俊杰,等.清脂化瘀方联合复方血栓通片对痰瘀互结型年龄相关性黄斑变性患者的临床疗效[J].中成药,2023,45(9):2901-2906.
[37] 黄滟凌,罗远湘,陈娟,等.雷珠单抗联合复方血栓通胶囊对年龄相关性黄斑变性患者血液流变学和血清VEGF、PDGF的影响[J].现代生物医学进展,2022,22(8): 1582-1585+1600.
[38] 陈文黎,张丽霞,魏宇娇,等.不同中成药联合雷珠单抗治疗wAMD临床疗效的网状Meta分析[J].中国中医眼科杂志, 2022,32(1):77-83.
|